Psychedelic Medicine

Association

Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors

Excerpts from the publication

Background:
Despite the growth of psychedelic research, psychedelic-assisted group psychotherapy (PAGP) has received little attention in comparison to individual psychedelic-assisted psychotherapy models.

Methods:
In this article, we aim to discuss the therapeutic potential of PAGP, as well as outline existing models and the challenges of this approach. Using Irvin Yalom’s 11 therapeutic factors of group therapy as a basic framework, we analyse current literature from clinical studies and neurobiological research relative to the topic of PAGP.

Results:
We argue that combining psychedelic substances and group psychotherapy may prove beneficial for increasing group connectedness and interpersonal learning, potentially enhancing prosocial behaviour with direct opportunities to practice newly acquired knowledge about previously maladaptive behavioural patterns. Challenges regarding this approach include a more rigid therapy structure and potential loss of openness from patients, which may be ameliorated by adequate therapeutic training.

Conclusion:
We hope for this article to support clinical research on PAGP by presenting a therapeutic framework and outlining its mechanisms and challenges.

Read more

Preliminary results from a community-based ayahuasca-assisted mental health program among a Yaqui Indigenous population in Sonora, Mexico

Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder

Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled Phase II study

Psychotherapy with Psilocybin for Depression: Systematic Review

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis